Johns Hopkins researchers have developed a single-cell, multispectral imaging platform called AstroPath for precise pathological analysis of cancer specimens.
The GAIN/iCat2 study and the Pediatric MATCH trial showed that molecular data has a significant impact on treatment recommendations for kids with cancer.
The model found that tumor surface area and age were inversely related to survival, while increased expression of IL-13Rα2 was a positive survival predictor.
The eNRGy trial demonstrated zenocutuzumab was the first prospective clinical validation of NRG1 fusions as actionable oncogenic drivers.
Researchers studying Perjeta and Herceptin in HER2-positive advanced solid tumors reported that the combination is efficacious in KRAS wild-type tumors.
The 20-year study showed the test provided an accurate assessment of the risk of long-term metastases and mortality for patients with localized prostate cancer.
The company is getting ready to offer cancer patients every type of molecular cancer diagnostics, including testing for minimal residual disease.
The study, which showed that the disease may not only result from tobacco exposure as previously thought, could lay the groundwork for targeted therapies.
NCI researchers performed a multi-platform study to elucidate the factors that can contribute to a patient's better-than-expected response to a drug.
The research showed that atezolizumab plus nab-paclitaxel provided survival benefits, as did an antibody-drug conjugate that was recently approved by the FDA.